[Asia Economy Reporter Hyunseok Yoo] Naivec, a peptide fusion bio company, has obtained approval from the Ministry of Food and Drug Safety for its tissue regeneration induction product. The approved product can be used not only for tissue regeneration in the dental field but also as a muscle and bone regeneration guide material used in orthopedics, indicating significant potential for sales growth through expanded application areas.
On the 2nd, Naivec announced that its absorbable periodontal tissue regeneration inducer, ‘Regenomatrix,’ recently obtained European certification and successfully received certification from the Ministry of Food and Drug Safety. Regenomatrix is a product used to induce regeneration of bone tissue or periodontal tissue during ‘guided bone regeneration’ and ‘guided tissue regeneration’ procedures based on biocollagen.
For dental use, it functions as a barrier between the gums and alveolar bone to induce regeneration of periodontal tissue. In particular, since it uses absorbable materials, it has the advantage of being completely decomposed within the human body within 4 weeks after implantation, ensuring safety.
A company official stated, “Regenomatrix, as an ‘absorbable periodontal tissue regeneration inducer,’ can primarily be used as a tissue regeneration treatment in the dental field, but it is also applicable as a muscle and bone regeneration guide material used in orthopedics, making it a product with great growth potential.” He added, “Since expanding collagen manufacturing facilities in 2015, Naivec has focused on developing collagen-related products to create future high value-added products, and Regenomatrix is the result of such strategic product development.”
He continued, “So far, we have developed various collagen product lines, obtained overseas certifications, and exported to the US and Europe through global distribution channels such as Straumann. Regenomatrix is also pursuing overseas certifications following domestic Ministry of Food and Drug Safety approval, and we plan to focus on expanding market share along with existing product lines,” he added.
Collagen is a fibrous protein found in parts of the human body such as skin, bones, and cartilage, serving as cell adhesion and cross-linking between cells. Especially, regenerative medicine collagen is developed for medical use by removing causative agents that trigger immune responses from collagen extracted from animal tissues. Market & Research forecasts that the global regenerative medicine collagen market size will grow from 510 billion KRW in 2017 to 830 billion KRW in 2022 with collagen that ensures safety and biocompatibility for human use.
Naivec plans to strengthen its biopharmaceutical business based on peptides, including pharmaceuticals, platform business, and protein therapeutics, as well as its high value-added bio collagen-based business group.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
